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Summary 
The chemokine eotaxin is unusual in that it appears to be a highly specific chemoattractant for 
eosinophils. Ligand-binding studies with radiolabeled eotaxin demonstrated a receptor on eo- 
sinophils distinct from the known chemokine receptors CKR-1  and -2. The distinct eotaxin- 
binding site on human eosinophils also bound RANTES (regulated on activation T  expressed 
and secreted) and monocyte chemotactic protein  (MCP)3.  We have now isolated a  cDNA 
from eosinophils, termed CKR-3, with significant sequence similarity to other well character- 
ized chemokine receptors. Cells transfected with CKR-3  cDNA bound radiolabeled eotaxin 
specifically and with high affinity, comparable to the binding affinity observed with eosino- 
phils. This receptor also bound R.ANTES and MCP-3 with high affinity, but not other CC or 
CXC chemokines. Furthermore, receptor transfectants generated in a murine B cell lymphoma 
cell line migrated in transwell chemotaxis assays to eotaxin, RANTES, and MCP-3, but not to 
any other chemokines. A  monoclonal antibody recognizing CKR-3  was  used to show that 
eosinophils, but not other leukocyte types, expressed this receptor. This pattern of expression 
was  confirmed by Northern blot with RNA from highly purified leukocyte subsets.  The re- 
stricted expression of CKR-3  on eosinophils and the fidelity of eotaxin binding to CKR-3, 
provides  a  potential  mechanism  for the  selective recruitment  and  migration  of eosinophils 
within tissues. 
C 
hemotactic  cytokines,  or  chemokines,  are  8-10-kD 
heparin-binding proteins that mediate a range of pro- 
inflammatory effects on leukocytes, such as chemotaxis, de- 
granulation, synthesis of  lipid mediators, and integrin activa- 
tion (1-3). The chemokines are related in primary structure 
with amino acid sequence similarities  ranging from 20  to 
70% and are traditionally divided into two families, CXC 
(~x  chemokines)  and  CC  ([3  chemokines),  based  on  the 
presence or absence  of an intervening amino  acid in the 
first of two conserved cysteine pairs.  CXC family members 
are primarily chemoattractants for neutrophils and include 
IL-8,  neutrophil-activating protein  (NAP)12,  and platelet 
factor (PF4), whereas the CC family members, which in- 
clude  macrophage  inflammatory  protein  (MIP)lo~,  -113, 
R.ANTES  (regulated  on  activation  T  expressed  and  se- 
1Abbreviations used in this paper: CKI~-I, chemokine  receptor 1; IL-8RA, 
IL-8 receptor A; MCP-1, monocyte chemotactic protein 1; MIP-lc~, 
macrophage inflammatory  protein 1ca; NAP-2, neutrophil-activating  pro- 
tein 2; RANTES, regulated on activation  T expressed  and secreted; RT 
reverse transcriptase; 7TMS, 7 transmembrane  spanning. 
creted), monocyte chemotactic protein (MCP-1,  MCP-2, 
MCP-3),  and  eotaxin,  generally  attract  other  leukocyte 
types such as monocytes, T  cells, basophils, and eosinophils 
(1-5). More recently, a chemokine called lymphotactin with 
a single cysteine pair in the molecule has been identified that 
attracts lymphocytes (6). 
The importance of chemokines in leukocyte trafficking 
has been demonstrated in several animal models. For exam- 
ple,  neutralizing antibodies to  IL-8 inhibit neutrophil re- 
cruitment  to  sites  of inflammation  such  as  endotoxin- 
induced pleurisy and reperfusion injury (7-9). Neutrophil 
recruitment is also impaired in IL-8 receptor knockout mice 
(10). MIP-lo~ knockout mice were shown to have reduced 
inflammatory responses to viral infection (11)  as  demon- 
strated by a delay in T  cell-dependent viral clearance of in- 
fluenza, and elimination of coxsackie virus-mediated myo- 
carditis.  Furthermore,  neutralizing  antibodies  to  MIP-lcx 
were  reported  to  influence  eosinophil  recruitment  into 
mouse lung in a model of antigen-specific airway inflam- 
mation (12). Finally, antibodies to MCP-1 were able to block 
monocyte recruitment in a granuloma model (13)  and to 
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type hypersensitivity-induced inflammation in rats (14). 
The  only human  CXC  chemokine  receptors character- 
ized to date are the IL-8 receptor A, (IL-8RA) which binds 
IL-8,  and  the  IL-8  receptor  B  (IL-8RB),  which  binds  a 
number  of CXC  chemokines  including  IL-8  and  GRO~ 
(15-17).  The  most  fully characterized CC  chemokine  re- 
ceptors include CK_R,-1 which binds MIP-let and RANTES 
with high affinity (18,  19) and CKR-2, which binds MCP-I 
with  high  affinity  and  MCP-3  with  lower  affinity  (20). 
CKR-2  has been  shown  to exist in two isoforms resulting 
from  the  use of an alternative splice site in isoform A  pro- 
ducing a  distinct cytoplasmic tail.  Isoform B,  which  is not 
spliced in  this  region,  has  been  shown  to  be  a  functional 
receptor for MCP-1  and -3 in binding and signal transduc- 
tion assays (20,  21).  More recently, Power et al.  (22)  have 
reported a new receptor called CKR-4; cRNA from this re- 
ceptor produces a Ca2+-activated chloride current in response 
to  MCP-I,  MIP-la,  and  RANTES  when  injected  into 
Xenopus laevis oocytes. All are members of the 7 transmem- 
brane-spanning  (7TMS)  G  protein-coupled  receptor  su- 
peffamily (23, 24). 
Eosinophils are selectively recruited into certain inflam- 
matory lesions as a result of IgE-mediated reactions, for in- 
stance in rhinitis and allergic asthma, and also in response to 
certain parasitic infections (25--28). A number ofchemoattrac- 
tants have been  identified for eosinophils, such as platelet- 
activating factor (29), C5a (30),  IL-16 (31), R.ANTES, and 
MCP-3  (32-35), although these chemoattractants also induce 
the  migration  of other  leukocyte cell  types.  The  chemo- 
kine eotaxin, however, first identified in guinea pig (4) and 
subsequendy in mouse (36) and human (5), is unusual in that 
it  is  selectively chemotactic  for  eosinophi[s.  Binding studies 
with  125I-labeled  eotaxin  and  peripheral blood  eosinophils 
strongly suggested that eotaxin binds a receptor on eosino- 
phils distinct from CKR-I  and -2, as specific binding cannot 
be  competed  with  MIP-lc~  or  MCP-1  (5).  This  finding 
would appear to eliminate CKR-4 as an eotaxin receptor as 
it is reported to signal with MIP-la  and MCP-1. Based on 
ligand binding and receptor cross-desensitization data using 
eosinophils, it was predicted that at least one additional re- 
ceptor exists that binds and signals in response to RANTES, 
MCP-3  (33, 35), and eotaxin (5), but not MIP-let. 
Because  of the  strong  correlation  between  eosinophil 
recruitment and tissue damage in allergic inflammatory dis- 
eases  such  as  asthma  (27,  37-40)  and  the  probable  role 
that eotaxin plays in such a response (4,  41-43),  molecular 
characterization  of the  eotaxin  receptor may  assist  in  the 
development of receptor antagonists that may have therapeu- 
tic value. We report here the identification of a eosinophil- 
specific 7TMS  G  protein-coupled receptor that  has signifi- 
cant sequence similarity to CKR-1  and -2. When expressed 
in a heterologous system, this receptor confers specific, high 
affinity  binding  of  radiolabeled  eotaxan,  RANTES  and 
MCP-3,  as well as the capacity of the transfectants to mi- 
grate chemotactically to these ligands. Furthermore, an anti- 
CKR,-3 mAb shows that it is expressed exclusively on  the 
surface of eosinophils. 
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Materials and Methods 
Cells, Cell Lines, and Tissue Culture.  Eosinophils were isolated 
from heparinized blood using CDt6  microbeads (Miltenyi Bio- 
tec, Auburn, CA), as described (5) and were shown cytologically 
to be  />99%  pure. Neutrophils and PBMC  were isolated as de- 
scribed (5). Monocytes were purified by CDI 4 positive selection 
with magnetic beads and T  cells by passage of }ymphocytes over 
nylon  wool.  To  generate  CD3  blasts,  2  X  106  PBMC/ml  in 
RPMI-1640  plus  10%  FCS were  added to  tissue  culture plates 
first coated with the anti-CD3 antibody TR77. After 4--6 d, blasts 
were removed to fresh media and supplemented with IL-2 (Gen- 
zyme Corp., Cambridge, MA) at 50 U/ml. 
Isolation of Genomic and eDNA Clones, Southern and Northern Hy- 
bridizations.  Two independent approaches were taken to clone 
novel  chemokine  receptors  from  eosinophils:  (a)  reverse  tran- 
scriptase  (RT)-PCR with eosinophil mRNA and degenerate oli- 
gonucleotides  based  on  known  chemokine  receptors,  and  (b) 
screening of a eosinophil eDNA library with the CKR-1  cDNA 
under low stringency wash conditions. 
For the RT-PCR approach, 20 ng of eosinophil mR.NA was 
reverse transcribed with oligo dT. 4 Ixl of this eDNA was mixed 
with 200  ~M  dNTP  and  100  pmol of degenerate primers in a 
50-~1  volume.  Primer pairs TM2a-I  and TM3R  were  used in 
the  first  reaction  in  60  mM  Tris-HCl,  pH  9.5,  and  1.5  mM 
MgCI  2. The cycle parameters were 3 cycles: 94~  30 s; 37~ 
30 s; 2-min ramp to 72~  1 min, followed by 30 cycles: 94~ 
45  s; 480( ",  1 min; 72~  1 rain. A second PCR  was performed 
with a nested primer TM2a-2 and the TM3R primer with reac- 
tion  conditions  exactly as  tbr  the  first  round.  The  R.T-PCR 
primers used to amplify receptor fragments from eosinophils were 
TM2a-I:  5'-TAC  ('TG  CTS  AAC  CTG  GCC  ITG  GCI  G, 
which primes in a conserved regmn within the second TM span- 
ning domain, and TM3R: 5'-GGC RTG GAC IAT GGC CA(; 
GTA RCG GTC, which primes in a highly conserved region just 
3' to the third TM spanning domain. The nested primer TM 2a- 
2:  5'-AC CTG  GCC  ITG  GCI  GA("  CTM  CTC  TT  corre- 
sponds to a region beginning 11 nucleotides 3' of the first nucleotide 
ofTM2a-l. PCR products were assessed and separated by agarose 
gel electrophoresis. A fragment of predicted size ('~200 bp) based 
upon  known  chemokine  receptors was  purified and  subcloned 
into pCR-Script  TM  (Stratagene Inc.,  La Jolla, CA) fbr sequence 
analysis.  This fi'agment was  used to probe a human  genomic li- 
brary (Clontech, Palo Alto, CA) a.s described (5). One clone, EosL2, 
contained  a  1.8-kb  Hindlll  fragment  predicted from  Southern 
hybridizations that was subcloned into pBluescript II KS+  (Strata- 
gene Inc.) for sequence analysis and further manipulation. 
For isolation ofcl)NA clones, eosinophils were obtained from 
a patient diagnosed with idiopathic hyper-eosinophilic syndrome. 
RNA was isolated using a standard guanidinium isothiocyanate/ 
cesium chloride method, rnRNA was obtained using Dynabeads 
(Dynal, Inc., Great Neck, NY), and a bacteriophage library was 
constructed using the SuperScript  TM  Lambda System for eDNA 
synthesis and kgt22A cloning arms (GIBCO BRL, Gaithersburg, 
MI)).  Approximately 750,000  PFU  were  screened with  a  full- 
length radiolabeled cl)NA probe encoding CKR.-1. The library 
was screened and phage isolated and purified using standard mo- 
lecular biological techniques  (44).  Phage inserts were subcloned 
into pBluescript for sequence analysis. 
Human genomic I)NA was purchased from CIontech and South- 
ern hybridization was as described (45).  For Northern hybridiza- 
tion, RNA was isolated using TriZOL  TM  reagent (GIBCO BRL) 
following the  manufacturer's recommended protocol.  15  I~g of 
total RNA was separated on 1.2% formaldehyde agarose gels and transferred  to  Nytran-Plus  TM  nylon  membrane  (Schleicher  & 
Schuell, Inc., Keene, NH) and cross-linked using a Stratalinker  | 
(Stratagene  Inc.).  Hybridizations with  radiolabeled  probe  was 
with ExpressHyb  TM  Solution (Clontech) using the manufacturer's 
suggested  protocol.  Length  of autoradiograph  exposure  is  de- 
scribed  in  appropriate  figure  legends.  For  hybridization,  a  3' 
untranslated  region  probed  specific  for  CKR-3  was  used  en- 
compassing  nucteotides  1203-1453  as  deposited  with  EMBL/ 
GenBank/DDBJ under accession number U49727. 
Expression Vector Construction and Generation of a CKR-3-express- 
ing Stable Cell Line.  PCR was used to modify the CKR.-3 gene 
contained in the 1.8-kb genomic fragment by inserting a HindlII 
restriction site and optimal Kozak sequence immediately 5' to the 
initiation codon.  The  coding region and 448  bp  of 3'  untrans- 
lated region were then cloned into the HindlII site of pcDNA3 
(Invitrogen, San Diego, CA). 
The murine pre-B lymphoma cell line L1.2 was obtained from 
Dr.  Eugene  Butcher  (Stanford  University,  Stanford  CA)  and 
maintained in RPMI-1640  supplemented with  10%  bovine se- 
rum. 20 p,g of linearized, CKR-3 in pcDNA3 was used to trans- 
fect the cell line as follows. L1.2 cells were washed twice in HBSS 
and resuspended in 0.8 ml of the same. The plasmid DNA was 
mixed with the cells and incubated for 10 min at room tempera- 
ture, transferred to a 0.4-cm electroporation cuvette, and a single 
pulse was  then applied at  250  V,  960  IxF.  The  electroporation 
was followed by a 10-min incubation at room temperature. G418 
was added to a final concentration of 0.8 mg/ml 48 h after trans- 
fection and the cells were plated in 96-well plates at 25,000 cells/ 
well. After 2-3 wk under drug selection, G418-resistant cells were 
stained with 5H12 antireceptor mAb (see below) and analyzed by 
FACScan  |  (Becton Dickinson & Co., Mountain View, CA). Lines 
with detectable surface staining were expanded and cloned several 
times by limiting dilution. Clones with the brightest surface stain- 
ing were further analyzed by Northern hybridization to confirm 
the presence oftransfected receptor as well as by RT-PCR. using 
a T7 primer present in the pcDNA 3 vector as the 5' primer and 
a CKP,-3-specific primer as the 3' primer (not shown). No am- 
plification was seen without addition of reverse transcriptase. For 
transient transfection, 20 p~g of supercoiled DNA was used in the 
electroporation exactly as described for stable cell line produc- 
tion. Cell surface staining was assessed after 48-72 h. Transfected 
cells were treated with 5 mM n-butyric acid for 24 h before ex- 
perimentation (46). 
mAb Production and Flow Cytometry.  mAbs reactive with CKtk-3 
were  generated by immunizing mice  with a  synthetic peptide, 
corresponding to the NH2-terminal 35 amino acids, coupled to the 
carrier protein PPD  (Severn Biotech Ltd., Cambridge, UK). Fe- 
male BALB/c mice were immunized with 50 p.g of this peptide- 
PPD  conjugate in PBS four times at 2-wk intervals. Mice were 
immunized intraperitoneally using CFA (first immunization) and 
IFA (subsequent injections). The final immunization was injected 
intravenously without adjuvant. 4 d later, the spleen was removed 
and cells  were  fused with the  SP2/0  cell line as described (47). 
mAbs reactive with synthetic peptide were screened by ELISA as 
follows. 50 ILl of peptide, at a concentration of 2  p~g/ml in car- 
bonate buffer,  was  used to  coat  96-well Maxisorp  plates for  at 
least  4  h  at  4~  (Nunc,  R.oskilde,  Denmark).  300  p  J/well  of 
blocking buffer (PBS  plus  1% BSA)  was  added for at least 2  h. 
Plates were washed four times with PBS/Tween 20, and 50 p,1 of 
mAb supematant was added to each well and incubated at 37~ 
for 1 h. Plates were washed four times with PBS/Tween 20, and 
alkaline phosphatase-conjugated  second  antibody  (Jackson  Im- 
munoR.esearch Laboratories, West Grove, PA)  diluted 1:500 in 
PBS was added to each well. After an incubation at 37~  for 30 
rain, plates were  washed four times with PBS/Tween 20.  The 
substrate used for the color reaction was p-nitrophenylphosphate 
dissolved in diethanolamine buffer (Bio-Rad Laboratories, Rich- 
mond, CA). Plates were read at 410 nm on an ELISA reader. 
To determine which antipeptide mAbs could recognize native, 
surface-expressed  CKR-3,  the  antipeptide  mAbs were  screened 
against transiently transfected cells and eosinophils. For mAb stain- 
ing, cells were washed once with PBS, and resuspended in 100 I*1 
PBS containing 2% FCS, 0.1% sodium azide (FACS  |  buffer), 5 p~g/ 
ml purified antibody, 5 I~g/ml MOPC-21 IgGl-isotype-matched 
control mAb (Sigma Chemical Co., St. Louis, MO), or 100 p~l hy- 
bridoma culture supernatant. After 30 rain at 4~  cells were washed 
twice with FACS  |  buffer, and resuspended in 100 ~1 FITC-conju- 
gated, affinity-purified F(ab')2 goat anti-mouse IgG (Jackson Immu- 
notkesearch Laboratories).  ARer incubating for 30 min at 4~  cells 
were washed twice in FACS  |  buffer and analyzed by FACScan  | 
to determine the level of surface expression. Propidium iodide was 
used to exclude dead cells. 
Chemokines, Chemotaxis Assays, and Ligand-binding Assay.  Re- 
combinant human  chemokines  were  obtained from  Peprotech 
(Rocky Hill, NJ) except for eotaxin, which was synthesized using 
solid-phase methods that were  optimized and adapted to  a fully 
automated peptide synthesizer (model 430A; Applied Biosystems, 
Foster City, CA) as described (48).  Chemotaxis experiments with 
L1.2 cells or L1.2 receptor transfectant cell lines were as described 
(5)  except that endothelial cells  were  not used to  coat the Bio- 
coat  |  transwell tissue culture inserts (Costar Corp.,  Cambridge, 
MA)  and the  incubation was for 4  h.  Chemotaxis  experiments 
with human eosinophils employed endothelial cells  to  coat the 
transwell inserts (5). 
12SI-labeled eotaxin was produced using the Bolton Hunter re- 
agent (NEN, Boston, MA), as described (47). The specific activity 
of radiolabeled eotaxin was calculated to be 180 Ci/mM. Chemo- 
kine  binding to  target  cells  was  carried  out  using a  modified 
method previously reported (49).  Cells were washed once in PBS 
and resuspended in binding buffer (50 mM Hepes, pH 7.5, 1 mM 
CaC1, 5 mM MgC12, 0.5% BSA, and 0.05% azide) at a concentra- 
tion of 107/ml. Miquots of 50 p~l (5  ￿  10  s cells) were dispensed 
into microfuge tubes, followed by the addition of cold competi- 
tor and radiolabeled chemokines as indicated in the text. The fi- 
nal reaction volume was 200 I.LI. Nonspecific binding was deter- 
mined by incubating cells  with radiolabeled chemokines in the 
presence of 250-500 nM of unlabeled chemokines. After 60 min 
incubation at  room  temperature,  the  cells  were  washed  three 
times with 1 ml of binding buffer containing 0.5 M  NaC1.  Cell 
pellets were then counted. The competition was presented as the 
percent specific binding as  calculated by  100  ￿  [(S-B)/(T-B)], 
where S is the radioactivity of the sample, B is background bind- 
ing,  and  T  is  total  binding without  competitors.  Background 
binding  was  obtained  by  incubating  cells  with  radiolabeled 
chemokine and at least 400-fold excess of unlabeled chemokines. 
Duplicates were  used throughout the experiments and the stan- 
dard deviations were always <10% of the mean. All experiments 
were repeated at least three times. Curve fit was calculated by Ka- 
leidaGraph software (Synergy Software, Reading, PA). 
Results 
Cloning of a CC Chemokine Receptor  fiom Eosinophits.  Two 
cloning approaches  were  taken,  one  using tkT-PCR  and 
degenerate  oligonucleotides and the  other  crosshybridiza- 
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the same sequence which had significant similarity to other 
7TMS  chemokine  receptors.  Both  eDNA  and  genomic 
clones were sequenced and found to contain an open read- 
ing frame of 1,065  nucleotides  encoding a protein of 355 
amino acids with a predicted molecular mass of 41  kD (Fig. 
1). Comparison with other chemokine receptor sequences 
revealed a 62, 47,  and 41% amino acid sequence similarity 
to  CKR-1,  -2B,  and  -4,  respectively.  In  contrast,  the 
amino acid sequence similarity to IL-8RA and IL-8RB was 
only 27% for both receptors. 
The CKR-3 gene codes for four cysteine residues,  one 
in  each  of the  extracellular  domains  at AA positions  24, 
106,  183,  and  273.  Cysteines  at these  positions  are  con- 
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Q K  R  H  -  L  V  K  F  V  C  L  G CIW  G LIS  M N  L  S[I_P_JFIFIL]FIR  Q A  Y  H  P  N  N  S  S  P  VlCIY  E  V  L  G  IL8RA 
TM5 
2~  I  zp  2~,  I  2~, 
189  E  S  L  R  E  WI-'K"-~FI-QA"[LI'-K--L-'N-"~F~-'G-IL  V  L  P  L  L  V  M~"lI  C  V  T  G  I  I  KITIL  L  RI-R'IP~N-E]K  KI  CC CKR1 
196  R  -  -  -  G WIN  NIF H--H-'T]'TM R  N[TFL-GIL  V  L  P  L  L[TIMIVlI  C  Yi-S1G  IF'C]KT  L  L  R'-CFR"N  ElK  K[  CCCKR2B 
z93  L N S T :  T wl K V--C--~ E x NIZI~ G!J..~J-~P Ll~" ZI,I,~C  YIS~-~IT  L~ K N ElK KI  CC CKR4 
197  NNF~_F~  AA -  NIW  RIM  L  L  R  X  L  P  Q  SlFIG  F  Z  rip  L~ZlM]L  FiC  YIG  F  T  L  RIT  ElF  K  -  A  H  M  G  Q  K  H  RiA I  TLgRB 
193  K  W R  P  L  V  M  C  Y  T  L  F  K  -  A  H  M  G  Q  K  H  RIAI  ILSRA 
1%16 
12p  z~e  z~  I  qe  ￿9  z~el 
238  L.~R  L  I  F  V  I  M~L_V.~F F~T~F  W T  P  Y  N,..V._~,I  Lr..I~S~Q~__.T..~L  F~-IC  Er.B_-T-_.K~H L  O Lr-.V...~_L~V T i  CC CKR3 
238  ViRr...~I  F~L,I  MII  IZLE.,FiLiF  W T  P  Y  NIL  TIT  LI!,ISlV  FIQIO  ElL  FIT  H  E  -IC  EIq.S_,S RLli, L  D,J.JA  V  QI v  T I  CC CKR1 
Z42  VlRrViI  FITII  MtIM.!.YIFI  LJF  W T  P  Y  NII  VL,T,...L~LiN T  FL.O.J E  F  F  G L  S  N  -JC  EIS[.!.JS  QiL  DIQ  A  T  QIVTI  CC CK,'~?.B 
241  V  K  M]I  FJA  V  V  V  LIFIL  GLE_W "f  P  Y  NiI  V  L,_[FILIE  T  L  V  E  L  E  V  L  Q~-  dT  F  E  R  Y  YJ_L. DiY  A  I  Q A1T  CC CKR4 
24s  M~vl,  F]A V V L  zlFIL  L~wlqP  Y NIL  V LILIA  0  T  L M R T Q V T Q E T  C E RIR  N~Z~R  A L D AIT  ZLSP.B 
241  MIRIVL,T._EJA  V  V  L  ILFJL  L  eL]ft.}LIp  Y  NIL  V  LILIA  D T  L  M R T  q  V  I  Q  E T  C  E  RtR  N  N  T  G R A  L  D AITI  ILSRA 
TM7 
zp  3~p  I  3p  3~  3~ 
287  E  V  I  A  Yr-%H  C  C,_B.~N P  V  I  Y  A  F  V  G E  R  F  R  K  Y  L  Rr_tLF_~  F  H R  / -~H  L  GRYI  P  F  L  P  S  E  K(  CC CKR3 
287  E,_.V_,T,_A_.YJ  TJH  C  CIVIN  P~V.~I  Y  A  F  V  G E  RF  R  K  Y  L_B.JQ LIF_Ii_.B.J -  R V  A  VIH  LIV  K  W LIP  F  LIs  V  D  R  CC CKR1 
291  EIT  L..GG M TIH  C  CIIIN  PITII  Y  A  F  V  G EIKIF  RIR'IY  L~S  Vi'-F-FtR  K  -i-H']T  T  K  R  F  C  K~CIPIV  F  Y  RI~'E'IT  CC CKRZB 
Z9e  EIT  L~AtF  VIH  C  CIL~N  PlIl~  Y[-~F~G~KIF  RK~__~L  Q L-C~K  T  C R  G~G  VFL~C  Q~C  G L[-~Q  I  Y  S  CC CKR4 
29slEIzLG~LIH~CILINPILl  YAFt~IGtQKtFRIHGL~LKZLAZ  ..........  HGLTSKOS  ZL,RB 
29z  L~Z  L  G  F  L~SlClLNL~IT  Y  A  FI~L~Q  NIFR~H  G  F  L  K  T  L  AM  ..........  H  G  L  V  S  K~F  TL~ 
~  3~, 
336  L  E  R~T..,S s~sl-  P  s  T,.J~E,_P_.,E  L  S,_,L_V_,F  CC CKR3 
336  IL  E  RIVLS.~SITISi  -I P  S  TIGIEIHIE~L.,SI  A  Gill  CC CKR1 
34~  V  O G V~.JSIT  N TLP_,S TJGLFJQ~A  G L  CC CKR2B 
340  A  D T  PlS  SIS  Y  T  QIS  TiM  DI,.I DLiJH  D A  L  CC CKR4 
335  ~  P  K  D L..,~ R  P i'~F  V  G  S  S  S  G  H  T I-S"  1T  T  L  ILRRB 
331  ~AI-R]H  R  V  TL_~.JY T  -  S  S  S  V  N VL,,~JS  N  L  IL8RA 
Figure 1.  Amino acid sequence alignment of CKR-3 with other human chemokine receptors. The sequences were aligned by the Clustal method us- 
ing MegAlign  TM  (DNASTAR, Inc., Madison, WI). Amino acids identical to CKI~-3 are boxed with numbers across the top of the sequence referenced 
to CKR-3. (*) Four conserved extracellular cysteines. These sequence data are available from EMBL/GenBank/DDBJ under accession number U49727. 
2440  A Human Eotaxin Receptor served in all chemokine  receptors  (asterisks,  Fig.  1).  In ad- 
dition,  this  receptor  contains  an  amino  acid  motif,  DRY- 
LAIVHA (amino acids  130-138,  Fig.  1), which  is also very 
highly  conserved  in all chemokine  receptors  and predicted 
to  be  intracellular.  There  are  two  consensus  sites  for pro- 
tein kinase C  phosphorylation  (50,  51): one in the third in- 
tracellular  loop  at  AA  position  231,  and  one  in  the  cyto- 
plasmic tail at AA position 333.  CKR-3  also contains  eight 
serine/threonine  residues in the cytoplasmic tail which may 
serve as phosphorylation sites for G protein-coupled receptor 
kinases such as those isolated from neutrophils  (52) or other 
related family members (53, 54).  Serine/threonine-rich  cy- 
toplasmic tails are also a common feature ofchemokine  re- 
ceptors.  Unlike  CKR-1,  -2,  -4,  IL-8RA,  and  IL-8RB 
receptors,  CKR-3  does not contain  sites for N-linked  gly- 
cosylation. 
The  nucleic  acid sequences  obtained  from genomic  and 
cDNA libraries were colinear except for a region  17 bp 5' to 
the initiation codon. Here the genomic clone appears to have 
an  intron  that  separates  the  promoter  and  most  of the  5' 
untranslated  region  from the  coding region.  This genomic 
arrangement  is similar in  other  7TMS  chemoattractant  re- 
ceptors  (55,  56),  including  IL-8R.A  and  IL-8RA3  (57-59) 
and CKR.-I  (19). Furthermore,  examination of the genomic 
sequence  around  the point  of divergence  reveals a  canoni- 
cal splice acceptor sequence  (not shown). 
We note that Combadiere  et al.  (60)  have recendy pub- 
lished a CKR-3-like  sequence  with specificity for MIP-Ia, 
-113, and RANTES.  However. in light of the recent retrac- 
tion of that data  (61), further experiments will be necessary 
before comparison with the present work can be made. 
la'gand  @ecifidty  of CKR-3.  Attempts  to  express CKR.-3 
in traditional  host cells such  as COS,  HEK 293,  and  CHO 
resulted in poor surface expression, yielding ambiguous ligand 
binding.  Antibodies  to  a  FLAG-tagged  receptor  (62)  re- 
vealed  that  only  2-5%  of the  cells  were  surface  positive 
whereas  substantial  intracellular  protein  could  be detected, 
indicating a problem with protein trafficking.  Therefore, to 
assess  ligand-binding  specificity  and  signal  transduction  of 
CKR-3,  the  clone  was  transfected  into  the  mouse  pre-B 
cell line  L1.2  as an alternative  host  cell line  in  which  high 
levels  of surface  expression  could  be  more  easily selected. 
This cell line has been used successfully for the study of other 
chemoattractant  receptors (63), and the expression oftrans- 
fected human  chemokine receptors confers specific chemo- 
tactic ability to various ligands (see below). To monitor sur- 
face  expression  of CKP,-3,  a  r/IAb  was  produced  to  the 
NH2-terminal  region  of the receptor,  by immunizing mice 
with a 35-amino acid, NH2-ternlinal synthetic peptide. Anti- 
peptide mAbs were detected by ELISA, and mAbs that rec- 
ognize the native receptor were identified  by their reactiv- 
ity  with  human  eosinophils,  as well  as by their  staining  of 
transient  transfectants.  Fig.  2  A  shows  detectable  surface 
staining of the transiently transfected receptor on a subpop- 
ulation  of L1.2  cells,  using  an  antireceptor  mAb,  5H12. 
Untransfected  L1.2  cells were  negative  (Fig.  2  B).  Because 
of the low levels of surface expression  in transient  transfec- 
tions,  a stable cell line was constructed  by limiting dilution 
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Figure  2.  Cell  surface staining of LI.2 cells and receptor transfectants 
with  anti-CKR-3  mAb, 5H12. LI.2  cells transiently transfected with 
CKP,-3  (A), LI.2  mock-transfected  control  cells (/3), and  the  stable 
CKR-3 transfectant cell line, E5 (C) were stained as described in Materi- 
als and Methods.  (Shaded plot) Background staining with  the  IgGt-iso- 
type-matched control mAb, MOPC-21.  (Solid line) Staining with the an- 
tireceptor mAb, 5H12 
cloning  of the  transfectants  and  selecting  for high  surface 
staining.  This  yielded  lines  that  had  much  higher  levels of 
receptor expression  (Fig.  2  C).  Northern  blot analysis con- 
firmed the  presence  of transfected  CKR-3  mRNA  in  one 
of the subclones,  designated ES, and its absence in untrans- 
fected L| .2 cells (Fig.  2  C,  inset). 
The E5  cell line was tested for its ability to bind radiola- 
beled  eotaxin.  Fig.  3  A  shows  that  the  transfected  cells 
bound  ~2SI-labeled eotaxin  specifically and with  high  aft]n- 
ity. Scatchard analysis of the binding data indicated a dissoci- 
ation constant (Ka) of 1.5 nM, similar to the value of 0.5 nM 
obtained  using  purified  human  eosinophils  (Fig.  3  B).  In 
addition,  both RANTES  and MCP-3  were able to specifi- 
caUy  compete  for  binding.  No  other  chemokines  tested, 
including  MIP-10t,  -113,  or  IL-8,  were  able  to  specifically 
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Figure 3.  Competitive ligand  binding of radiola- 
beled human eotaxin to L1-2/CKR-3  transfectant 
(A) and human eosinophils (/3). Cells were incu- 
bated with 0.6 nM 12Sl-labeled  eotaxin and various 
concentrations  of unlabeled  eotaxin (O), RANTES 
(&), and MCP-3 ([7). After 60 min at room tem- 
perature, cell pellets were washed and  counted. 
The total binding of eotaxin to CKR-3  transfec- 
tants was 11,611 +  119 cpm and background  bind- 
ing was 2,248 + 745 cpm. The total binding ofeo- 
taxin to  eosinophils was  7,866 -+  353  cpm and 
background binding 1,148 +  518 cpm. Scatchard 
plot of unlabeled eotaxin competition was calcu- 
lated from the data and presented on the right of 
the binding curves. 
CKR-3 Expression  in L1.2 Cells  Confers  Chemotactic Abili- 
ty to Eotaxin, RANTES,  and MCP-3.  To  further investi- 
gate  the  ligand specificity of CKR-3,  the  L1.2  receptor 
transfectants were tested for their ability to  migrate in re- 
sponse to a panel ofchemokines over a range of doses (Fig. 5). 
The CKR-3-expressing cell line showed a chemotactic re- 
sponse to eotaxin, RANTES, and MCP-3 with a peak re- 
sponse to eotaxin at 100 ng/ml, although specific migration 
could be detected as low as 10 ng/ml (Fig. 5 A). Whereas a 
response to RANTES was evident at both 10 and 100 ng/ml, 
the magnitude of the response was not as great as with eo- 
taxin. MCP-3 appeared to be a less potent chemoattractant 
on the transfected cell line than on eosinophils (5,  33; see 
below) with no detectable migration below 100 ng/ml. No 
significant response  to  other  chemokines tested  was  seen 
Figure  4.  Inhibition of eotaxin binding by various chemokines. L1-2/ 
CKR-3 transfectants were incubated with 0.6 nM radiolabeled eotaxin 
and 250 nM unlabeled  chemokines  or no competitor as indicated. 
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with this  cell line. Furthermore,  in other control experi- 
ments, cells did not migrate to the bottom chamber when 
chemokine was added to the top well alone, confirming that 
cell migration was  chemotactic  rather  than  chemokinetic 
(not shown).  Fig.  5  B  shows  that  the  untransfected L1.2 
cell line did  not migrate  in response  to  any chemokines 
tested.  Indeed, a  striking feature  of the L1.2  cell line was 
the very low background chemotaxis to nonspecific ligands. 
As a specificity control, L1.2 cells transfected with IL-8RB 
migrated specifically to IL-8 and GROoL (Fig. 5  C) as well 
as to  NAP-2 and ENA-78  (not shown), but not to  other 
CXC or CC chemokines. Other chemokine receptors we 
have  transfected  into  L1.2  cells  also  confer  chemotactic 
ability to their specific ligands, including CKR-2 transfec- 
tants to MCP-1  and -3,  CKR-1  transfectants to MIP-lix, 
and  IL-8RA transfectants  to  IL-8  (not  shown).  Pertussis 
toxin  completely  abrogated  the  chemotactic  response  of 
both eosinophils and the  CKR-3 transfectants to  eotaxin, 
indicating that the receptor was signaling through the  Got 
subclass  (64)  in  both  normal  and  transfected  cells  (not 
shown). 
The Chemotactic Profile of Eosinophils Resembles that of CKR-3 
Transfectants.  To  assess whether  the  function of normal 
eosinophils resembled  that  of CKR.-3  L1.2  transfectants, 
chemotaxis experiments were performed using eosinophils 
from  normal  individuals with  high  levels  of eosinophils 
(:"6-8% of white blood cells).  Fig. 6 shows two character- 
istic patterns of eosinophil chemotaxis observed in two dif- 
ferent individuals. One pattern was characterized by a robust 
migration to  eotaxin,  and a  lesser  response  to  RANTES 
and MCP-3  (Fig.  6  A).  The other pattern showed  essen- 
tially "equivalent  chemotaxis  to  eotaxin,  RANTES,  and 
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Figure 6.  The chemotactic response of eosinophils from some individu- 
als resembles that of CKR-3 L1.2 transfectants. Donor to donor variation 
of chemotactic  responses of eosinophils  to eotaxin,  RANTES, MCP-3, 
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Figure 5.  Transwell chemotaxis of the L1.2 cell line and 
L1.2 receptor transfectants.  10  6 cells of the CKR-3 trans- 
fected cell line E5 (A), the parental L1.2 cell line (B), and 
the IL-8 RB L1.2 receptor transfectant line LSLW-2  (C) 
were  placed  in  the  top  chamber  and  chemokines  were 
placed in the bottom chamber  at the concentrations  speci- 
fied. Migration  was allowed for 4 h and cells migrating  to 
the bottom chamber were counted as described in Materi- 
als and  Methods.  All assays were performed in duplicate 
and the results are representative  of at least three separate 
experiments.  Chemokines are listed along the x-axis, num- 
ber of cells migrated  (as described in Materials and Meth- 
ods)  along  the  y-axis,  and  concentration  of chemokine 
along the z-axis. 
assay,  since within each individual, they were reproducible 
over  6  months.  MIP-I~x  showed  only  weak  chemotactic 
activity for eosinophils in the second class of individuals. 
CKR-3  Is Expressed  Selectively  on Eosinophils.  Although 
eotaxin is thought  to be a specific chemoattractant  for eosi- 
nophils,  CKR-3  also binds  R_ANTES and  MCP-3,  which 
are known to attract monocytes and T  cells. Therefore, mes- 
sage  expression  of the  receptor  was  examined  in  various 
leukocyte populations.  Because of the high sequence simi- 
larity of CKR.-3 to other CC  chernokine receptors and the 
fact  that  the  full-length  clone  hybridizes  to  multiple  se- 
quences in  Southern  blots,  we selected as a  probe  a  3'  un- 
translated region fragment that does not crosshybridize with 
other sequences in Southern blots (Fig. 7  A). Fig. 7  B shows 
a  Northern  blot  panel  of leukocyte  populations  including 
monocytes,  neutrophils,  lymphocytes,  T  cells, T  cell blasts 
produced  by  activation  with  CD3  mAb,  and  eosinophils. 
The  only cell population  that  gave a  detectable  signal  was 
eosinophils, where a message  1.8 kb in size was found. 
and MIP-I~ was observed. Eosinophils were purified from blood and as- 
sessed for their chemotactic  response to various concentrations  of chemo- 
kines as described in Materials and Methods. Values are from a representa- 
tive experiment of at least four performed,  using  the  same two  blood 
donors. Figure 7.  Southern  and Northern hybridization analysis 
of CKR-3. (A) 10 I.zg of human genomic DNA digested 
with restriction enzymes indicated was probed with a 250- 
bp DNA fragment from the 3' untranslated region of the 
CKR-3  gene.  The  autoradiograph  was  exposed  to 
X-OMAT AlL film (Eastman Kodak, Rochester,  NY) for 
48 h with intensifying screen. Size markers are indicated 
on the left. (B) 15 I~g of total RNA isolated from highly 
purified leukocyte  populations was blotted  onto Nytran- 
Plus  TM membrane and probed with the same 3'untranslated 
region.  Northern blots were  exposed  to  X-OMAT AR 
film for  5  d  with intensifying screen.  Ribosomal RNA 
bands are  indicated  on the left. CICR-3-specific  probed 
was  removed  by boiling in 0.5%  SDS  and the blot re- 
probed with [3-actin to control for variation in loading. 
To  examine surface  expression  of CKR-3,  various leu- 
kocyte  types  were  stained with  the  mAb  5H12  and  ana- 
lyzed  by  flow  cytometry.  Highly  purified  eosinophils 
stained  strongly with  5H12  (Fig.  8),  suggesting abundant 
expression  of the  receptor  on  the  surface  of eosinophils. 
This  is  consistent  with  the  high  receptor  number  deter- 
mined by ligand binding and Scatchard  analysis (5).  Neu- 
trophils, blood T  cells, and monocytes showed little or no 
staining with this mAb (Fig. 8). 
Discussion 
In recent years,  a  novel family of G  protein-coupled re- 
ceptors has been cloned and characterized  (Table  1);  all of 
the receptors show a high degree of relatedness (Fig.  1) and 
share as ligands various members of the chemokine family. 
These receptors  transduce a  range of physiologic responses 
by host cells, from Ca  2+ flux and granule release to integrin 
expression,  chemotaxis,  and  most  recently,  inhibition  of 
HIV replication (65).  Their initial characterization  on leu- 
kocytes has prompted the observation that they participate 
in host-immune responses;  chemokine  neutralization; tar- 
geted  gene  disruption  studies  support  this  concept.  One 
Table 1.  Chemokine  Receptor Profiles 
Receptor  Chemokines that bind and signal  Reference 
IL-8RA 
Figure  8.  Examination of CKR-3  expression  on  leukocytes,  using  IL-8R]3 
mAb 5H12 and flow cytometry. Leukocyte subsets were prepared as de-  CKR-1 
scribed in Materials and Methods,  and stained with anti-CKR-3 mAb 
5H12  (solid lines) or MOPC-21 control antibody (shaded  profile). (A) eosi-  CKR-2 
nophils; (B) T cells; (C) monocytes; and (D) neutrophils. Dead cells were  CKR-3 
excluded based on propidium iodide staining. Staining profiles were repre-  CKR-4 
sentative of at least four experiments.  T  cells were  identified based on 
CD3 staining. Monocytes and neutrophils were identified by forward and  CKR-5 
side scatter. 
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IL-8  17 
IL-8, GROee/[3, NAP-2, ENA-78  15 
MIP-lot, RANTES, MCP-3  18,  19 
MCP-1, MCP-3  20, 21 
Eotaxin, R_ANTES, MCP-3  This report 
MIP-lcq R_ANTES, MCP-1  22 
MIP-lot, MIP-I[3, RANTES  76 characteristic of these receptors is their ability to bind sev- 
eral  chemokines.  In addition,  the  chemokines themselves 
usually bind more than one receptor. Less clear, however, 
is the distribution of these receptors among the various leu- 
kocyte classes.  The  eosinophil  has  attracted our attention 
because  of its  importance  in  certain  pathologies  and  be- 
cause of the uncertainty as to which receptor(s) is responsi- 
ble for its selective recruitment. 
A  number of studies have demonstrated strong chemo- 
tactic responses by eosinophils to RANTES,  MCP-3,  and 
lately, eotaxin (5). The receptor on eosinophils that was re- 
sponsible for this cheinotaxis was originally thought to be 
CKR-1, the MIP-lot/RANTES receptor, but intracellular 
calcium ([Ca2+]i) desensitization and ligand-binding studies 
implicated the existence of a distinct eosinophil receptor (5, 
33,  35).  We have cloned and characterized a receptor we 
call CKR-3 whose characteristics match those predicted for 
a  eosinophil  receptor.  When  transfected  into  L1.2  cells, 
CKR-3  binds  eotaxin,  R.ANTES,  and  MCP-3,  but  not 
MIP-lot  and  confers  chemotactic  responses  to  eotaxin, 
RANTES,  and MCP-3.  CKI~-3 is expressed on the  sur- 
face of eosinophils at high levels, as revealed by mAb stain- 
ing, and it is absent from other leukocyte types. 
The figand-binding experiments using CKR-3 transfec- 
tants indicate that CKP,.-3 is a high affinity receptor for eo- 
taxin,  and  also  recognizes  RANTES  and  MCP-3.  The 
chemotaxis  of CKR.-3  L1.2  transfectants  was  consistent 
with  this  binding  pattern,  since  CKR-3  transfectants  mi- 
grated in accord with the binding affinities of the chemo- 
kines.  The  hgand  binding  and  chemotactic  properties  of 
the CKR-3 L1.2 transfectants resembled the ligand binding 
and chemotactic properties of human eosinophils. This would 
suggest  that  CKR-3  is  one  of the  relevant  receptors  for 
normal eosinophil chemotactic responses, although we do 
not discount the possibility that other CC chemokine re- 
ceptors may play a role. Eotaxin could compete effectively 
for all of the RANTES and MCP-3  binding sites on hu- 
man eosinophils  (5),  suggesting that most if not all  of the 
RANTES  and  MCP-3  activity  on  human  eosinophils  is 
through a eotaxin receptor. Nevertheless, human eosinophils 
from some individuals may express a small number of other 
receptors, since eosinophils from these donors show a small 
degree  of  [Ca2+]i  flux  and/or  chemotactic  responses  to 
MIP-let (reference 5 and Fig. 7). The role of MIP-lc~ as a 
eosinophil chemoattractant has been controversial; some in- 
vestigators detect chemotactic responses (32), whereas others 
do not (5, 66). Interestingly, MIP-le~ is a strong eosinophil 
chemoattractant in the mouse, and this appears to be medi- 
ated  through  the  mufine  CKR-3  homologue,  which  also 
binds and signals with murine eotaxin (Gerard, C. and J.-C. 
Gutierrez-Ramos, manuscript in preparation). 
The dose-response profile for chemokine-stimulated che- 
motaxis  of the  L1.2  transfectants  matches  the  eosinophil 
profile  in  qualitative,  but  not  quantitative  terms.  This  is 
particularly seen in the case of MCP-3,  which is a potent 
agent on eosinophils but not L1.2 transfectants. This con- 
trasts  with the IL-8R transfectants, which are very respon- 
sive to IL-8. Although complex, the preponderance of evi- 
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dence  now favors the  G  protein activation of PLC,  with 
subsequent release ofinositol phosphates and [Ca2+]i as the 
initial steps in leukocyte locomotion (67,  68).  The lack of 
potency of CK_R.-3 in promoting chemotaxis may reflect a 
lack of efficient coupling between the receptor, G  protein 
subunits, and the PLC isoform in these cells.  In agreement 
with this is the observation that the IL-81L-transfected L1.2 
cells demonstrate a vigorous calcium flux in response to IL-8, 
whereas there is a weak signal, if any, detected for CKR- 
3--stimulated cells. 
In granulocytes, the PLC isoform 13 2 is activated by the 
[~/~/G protein subunits (69).  Other PLC isoforms are acti- 
vated by the ~x subunits (70).  Since the IL-8P,. and CKR-3 
transfectants are pertussis toxin sensitive, we may conclude 
that each receptor is coupled to an o~ i subunit.  However, 
the identities of the PLC isoform and the 13/~/subunits are 
unknown.  In future experiments,  the L1.2 cells  may pro- 
vide an interesting system to study the role of 13/"y subunits 
and the PLC in receptor coupling to chemotaxis via CKR-3. 
The CKR-3 has several features that distinguish it from 
other CC chemokine receptors identified to date. First,  it is 
expressed  at  a  high  level,  ~40,000-50,000  sites  per  cell, 
compared to CKR-1  and -2  which  are usually expressed 
on monocytes and T  cells at <3,000 sites per cell (71, 72). 
Neutrophils express ~40,000--60,000  IL-8R per cell (73), 
suggesting that  cells  of the  granulocytic  lineage  generally 
express high levels ofchemokine receptors. Neutrophils and 
eosinophils  are  two  of the  most  responsive  cell  types  in 
chemotaxis assays, although whether this relates to receptor 
levels is uncertain. The second unusual feature of CKR-3 is 
its restricted expression, since most chemokine receptors are 
expressed on  a  number of leukocyte types.  Although  we 
have not detected message in resting or activated T  cells, we 
cannot rule out the possibility  that a minor subset of T  cells 
may express this receptor. Restricted expression of CKR-3 
on eosinophils may correlate with the need for highly se- 
lective recruitment of these cells,  for instance, in response 
to certain parasitic infections (25-27)  and also in some in- 
flammatory settings, such as asthma (26,  28). This selective 
recruitment  presumably relates  to  the  specific functions  of 
eosinophils, such as killing of parasites, although their role 
in airway inflammation is not fully resolved. Another un- 
usual  feature  of CKR-3  is  the  lack  of an  NH2-terminal 
N-linked glycosylation site, which is a conserved feature of 
many  of the  7TMS  receptors,  although  murine  CKR.-3 
and -1 also lack this site (74). 
The eotaxin-CK1L-3 interaction provides a mechanism 
for the selective recruitment of eosinophils. This could be 
achieved at two levels: first, the CKR-3 is highly restricted 
in  its expression to  eosinophils.  Second,  eotaxin binds  to 
and signals  through this receptor with a high degree of fi- 
delity, unlike, for instance, MCP-3 which binds CKR-1, -2 
(75),  and -3 (this report), and MIP-le~ which binds CKI<-I 
and -4 (18,  22).  Indeed, eotaxin is possibly the only exam- 
ple of a chemokine that functions through a single recep- 
tor. Thus the production of eotaxin within a tissue might 
be expected to lead to selective eosinophil recruitment, and 
in support of this notion, we have observed that eotaxin in- jection into  the  skin of rhesus  monkeys leads to  selective 
eosinophil migration (5). In these in vivo experiments, eo- 
taxin was  shown  to  recruit eosinophils at a  10-fold lower 
dose than RANTES,  similar to the in vitro chemotaxis of 
CKR-3  transfectants.  In addition, at high doses RANTES 
clearly recruits mononuclear cells to skin sites (5), an obser- 
vation not made with eotaxin. 
In conclusion, we have identified an important chemo- 
kine receptor on human  eosinophils that appears to be the 
primary receptor for eotaxin, RANTES, and MCP-3 bind- 
ing, and also for the chemotactic responses ofeosinophils to 
these  three  chemokines.  The  discovery  of this  receptor, 
and identification of its counter ligands, provide a basis for 
understanding  the  nature  and  circumstances of eosinophil 
recruitment to inflammatory sites. Disrupting eotaxin-CKR-3 
interaction may prevent eosinophil recruitment  to  tissues, 
similar to the way in which IL-8R disruption inhibits neu- 
trophil migration to certain inflammatory sites (9,  10). 
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